Next Article in Journal
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy
Next Article in Special Issue
Cholera Toxin Subunit B as Adjuvant––An Accelerator in Protective Immunity and a Break in Autoimmunity
Previous Article in Journal
CpG Oligonucleotides as Cancer Vaccine Adjuvants
Open AccessReview

Gavi HPV Programs: Application to Implementation

Gavi The Vaccine Alliance Secretariat, 2 Chemin des Mines, Geneva 10 CH-1211, Switzerland
Department of Obstetrics and Gynecology, University of Washington, Box 359865, 325 9th Avenue, Seattle, WA 98104, USA
World Health Organization, Department of Immunization, Vaccines and Biologicals, 20 Avenue Appia, Geneva 27 CH-1211, Switzerland
Author to whom correspondence should be addressed.
Academic Editor: Vasso Apostolopoulos
Vaccines 2015, 3(2), 408-419;
Received: 23 February 2015 / Revised: 24 April 2015 / Accepted: 12 May 2015 / Published: 20 May 2015
(This article belongs to the Special Issue Vaccine Delivery)
Developing countries disproportionately suffer from the burden of cervical cancer yet lack the resources to establish systematic screening programs that have resulted in significant reductions in morbidity and mortality in developed countries. Human Papillomavirus (HPV) vaccination provides an opportunity for primary prevention of cervical cancer in low-resource settings through vaccine provision by Gavi The Vaccine Alliance. In addition to the traditional national introduction, countries can apply for a demonstration program to help them make informed decisions for subsequent national introduction. This article summarizes information from approved Gavi HPV demonstration program proposals and preliminary implementation findings. After two rounds of applications, 23 countries have been approved targeting approximately 400,000 girls for vaccination. All countries are proposing primarily school-based strategies with mixed strategies to locate and vaccinate girls not enrolled in school. Experiences to date include: Reaching marginalized girls has been challenging; Strong coordination with the education sector is key and overall acceptance has been high. Initial coverage reports are encouraging but will have to be confirmed in population based coverage surveys that will take place later this year. Experiences from these countries are consistent with existing literature describing other HPV vaccine pilots in low-income settings. View Full-Text
Keywords: HPV; vaccination; cervical cancer HPV; vaccination; cervical cancer
Show Figures

Figure 1

MDPI and ACS Style

Hanson, C.M.; Eckert, L.; Bloem, P.; Cernuschi, T. Gavi HPV Programs: Application to Implementation. Vaccines 2015, 3, 408-419.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

Only visits after 24 November 2015 are recorded.
Search more from Scilit
Back to TopTop